Health ministry appoints 2 Govt analysts for all classes of drugs as per Drugs and Cosmetics Act

Published On 2021-04-06 12:17 GMT   |   Update On 2021-04-06 12:17 GMT

New Delhi: Through a recent gazette notification, the Union Health Ministry has notified two government analysts in respect of all classes of drugs at Regional Drugs Testing Laboratory (RTDL), Chandigarh.

In exercise of the power conferred by sub-section (2) of section 20 of the Drugs and Cosmetics Act, 1940 (23 of 1940), the Central Government has appointed Shri Hitesh Kumar Khare and Dr Debasis Maiti at Regional Drugs Testing Laboratory, Chandigarh as Government Analysts for pan India in respect of all classes of drugs, except the few classes of drugs mentioned below listed.

According to the sub-section (2) of section 20 of the Drugs and Cosmetics Act, 1940 (23 of 1940) the Central Government may also, by notification in the Official Gazette, appoint such persons as it thinks fit, having the prescribed qualifications, to be Government Analysts in respect of such drugs or [classes of drugs or such cosmetics or classes of cosmetics] as may be specified in the notification.

Now as per the recent gazette notice, in exercise of the powers conferred by sub-section (2) of section 20 of the Drugs and Cosmetics Act, 1940 (23 of 1940) read with rule 44 of the Drugs Rules, 1945, the Central Government hereby appoints Shri Hitesh Kumar Khare and Dr. Debasis Maiti as Senior Scientific Officer-II at Regional Drugs Testing Laboratory, Chandigarh, to be the Government Analysts for the whole of India in respect of all classes of drugs, except the classes of drugs mentioned below, namely:―

(i) Sera;

(ii) Solution of Serum Proteins intended for injection;

(iii) Vaccines (parenteral and Oral);

(iv) Toxins;

(v) Antigens;

(vi) Anti-toxins;

(vii) Sterilized Surgical Ligature and Sterilized Surgical Sutures;

(viii) Bacteriophages;

(ix) Anti-sera for veterinary use;

(x) Vaccine for veterinary use;

(xi) Toxoid for veterinary use;

(xii) Diagnostic Antigens for veterinary use;

(xiii) VDRL Antigen;

(xiv) Intra-Utrine Devices and Falope Rings;

(xv) Human Blood and Human Blood Products;

(xvi) Blood Grouping reagents and diagnostic kits for Human Immunodeficiency Virus, Hepatitis B surface antigen and Hepatitis C Virus; and

(xvii) Condom

The Regional Drugs Testing Laboratory (RDTL) - Chandigarh is one of the Seven National Drugs Testing Laboratories of Central Drugs Standard Control Organisation (CDSCO), which has been in operation since November 2007 to meet the demand for drug and cosmetic testing. The Laboratory has been developed for the Quality Control of Drugs & Cosmetic products with respect to Infrastructure, Equipment and Manpower for the Chemical, Instrumentation and Microbiological analysis.

Also Read:CDSCO Flags 14 Drug Samples Including Aspirin, Rosuvastatin As Not Of Standard Quality

The RDTL - Chandigarh tests a large number of legal (Form-18), survey, and imported samples of drugs and cosmetics obtained from CDSCO North Zone – Ghaziabad, Sub Zone – Baddi, Jammu, Varanasi, and Assistant Drugs Controller (India), Indira Gandhi International Airport, New Delhi on a regular basis. Aside from that, laboratory is notified for the State of Haryana, Himachal Pradesh, Jammu & Kashmir, Union Territories of Chandigarh and Delhi for the analysis of Drugs & Cosmetic samples drawn by their Drug Officers.

The laboratory has a testing capacity of about 5000 - Samples, per annum, and it is NABL Accredited as per ISO / IEC 17025:2005, since 2016.

Also Read:CDSCO Declares 16 Drug Samples Including Clopidogrel, Aspirin Tablets As Not Of Quality Standard

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News